Immunotherapy after surgery offers recurrence-free survival advantage for patients with high-risk melanoma

Patients with high-risk melanoma who had a course of pembrolizumab after their surgery had a longer time before their disease recurred than patients who got either ipilimumab or high-dose interferon after surgery.